scholarly journals Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies

Respiration ◽  
2018 ◽  
Vol 96 (3) ◽  
pp. 210-221 ◽  
Author(s):  
Hideaki Yamakawa ◽  
Eri Hagiwara ◽  
Hideya Kitamura ◽  
Tae Iwasawa ◽  
Ryota Otoshi ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Pulmonary Function ◽  
Lung Disease ◽  
Predictive Factors ◽  
Trna Synthetase ◽  
Aminoacyl Trna Synthetase

Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease

2020 ◽  
Vol 58 (2) ◽  
pp. 83-90 ◽  
Author(s):  
Reoto Takei ◽  
Yasuhiko Yamano ◽  
Kensuke Kataoka ◽  
Toshiki Yokoyama ◽  
Toshiaki Matsuda ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Predictive Factors ◽  
Trna Synthetase ◽  
Aminoacyl Trna Synthetase

scholarly journals The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies

2017 ◽  
Vol 127 ◽  
pp. 57-64 ◽  
Author(s):  
Kiminobu Tanizawa ◽  
Tomohiro Handa ◽  
Ran Nakashima ◽  
Takeshi Kubo ◽  
Yuji Hosono ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Trna Synthetase ◽  
Aminoacyl Trna Synthetase ◽  
Term Outcome ◽  
Long Term Outcome

scholarly journals Management of Myositis-Associated Interstitial Lung Disease

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 347
Author(s):  
Tomoyuki Fujisawa
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Current Knowledge ◽  
Strong Predictor ◽  
Calcineurin Inhibitors ◽  
Pulmonary Involvement ◽  
Trna Synthetase ◽  
Evidence Based Guidelines ◽  
Substantial Heterogeneity

Idiopathic inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM), are a diverse group of autoimmune diseases characterized by muscular involvement and extramuscular manifestations. Interstitial lung disease (ILD) has major pulmonary involvement and is associated with increased mortality in PM/DM/CADM. The management of PM-/DM-/CADM-associated ILD (PM/DM/CADM-ILD) requires careful evaluation of the disease severity and clinical subtype, including the ILD forms (acute/subacute or chronic), because of the substantial heterogeneity of their clinical courses. Recent studies have highlighted the importance of myositis-specific autoantibodies’ status, especially anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl tRNA synthetase (ARS) antibodies, in order to evaluate the clinical phenotypes and treatment of choice for PM/DM/CADM-ILD. Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD. Rapidly progressive DM/CADM-ILD with the anti-MDA5 antibody is the most intractable condition, which requires immediate combined immunosuppressive therapy with GCs, CNIs, and intravenous cyclophosphamide. Additional salvage therapies (rituximab, tofacitinib, and plasma exchange) should be considered for patients with refractory ILD. Patients with anti-ARS antibody-positive ILD respond better to GC treatment, but with frequent recurrence; thus, GCs plus immunosuppressants (TAC, CsA, azathioprine, and mycophenolate mofetil) are often needed in order to achieve favorable long-term disease control. PM/DM/CADM-ILD management is still a therapeutic challenge for clinicians, as evidence-based guidelines do not exist to help with management decisions. A few prospective clinical trials have been recently reported regarding the treatment of PM/DM/CADM-ILD. Here, the current knowledge on the pharmacologic managements of PM/DM/CADM-ILD was mainly reviewed.

Influence of obesity in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies

2022 ◽  
pp. 106741
Author(s):  
Koichi Yamaguchi ◽  
Yasuhiro Fukushima ◽  
Aya Yamaguchi ◽  
Miki Itai ◽  
Yuki Shin ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Trna Synthetase ◽  
Aminoacyl Trna Synthetase

Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease

2021 ◽  
Author(s):  
Takuma Katano ◽  
Akimasa Sekine ◽  
Satoshi Ikeda ◽  
Hideaki Yamakawa ◽  
Toshihiro Misumi ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Predictive Factors
Sign in / Sign up

Export Citation Format

Share Document